IGF-1 LR3 / BPC-157 / TB-500 Blend
The three-way repair stack — 11mg total, all components preclinical.
For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.
About IGF-1 LR3 / BPC-157 / TB-500 Blend
An 11mg vial containing 5mg BPC-157, 5mg TB-500, and 1mg IGF-1 LR3, also offered with arginine-salt BPC-157. It is the most expensive blend in the catalog and combines the two most popular repair peptides with a growth-signalling component, each acting through different pathways. Every component is preclinical for its marketed use, so the blend is too — and the same caution applies as for TB-500 individually: vendors use "TB-500" and "Thymosin Beta-4" for the same product, and the human trial evidence for that molecule comes from an ophthalmic eye-drop formulation, which says nothing about injected tissue repair. The fixed ratio compounds across three components with very different conventional dose scales, and the IGF-1 LR3 fraction still lowers blood glucose. No study has examined this combination, and at three components the number of untested interactions grows faster than the evidence does.
Key Benefits
- Three distinct repair and growth mechanisms in one vial
- Arginine-salt BPC-157 option offered for improved stability
- Avoids three separate reconstitutions
Set a goal (top of the page) to see how IGF-1 LR3 / BPC-157 / TB-500 Blend scores against it, and what the better-evidenced alternatives are.
Category Ratings
How to Take
Common Side Effects
- Hypoglycaemia from the IGF-1 LR3 component
- Injection site irritation
- Temporary lethargy
- Theoretical risk of promoting growth in existing tumours
- Fixed three-way ratio compounds dosing compromises
Legal & Regulatory Status
Research use only; not FDA-approved. All three components are preclinical for these uses; no study exists on the combination. IGF-1 LR3 is WADA-prohibited.
Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.
Research & Sources
- BPC-157 multifunctionality & possible medical application — literature review (PMID 40005999)
- Thymosin β4 (RGN-259) improves dry eye — phase 2 RCT; ophthalmic route, not injected (PMID 25826322)
- Des(1-3)IGF-I and IGF-I analogue potency — IGFBP escape mechanism context (PMID 8930132)
Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.
Prices at quality-checked sources · as of August 2026 (8 days ago)
- 5mg BPC-157 + 5mg TB-500 + 1mg IGF-1 LR3 (11mg total) $349.9511mg total, BPC-157 Arg form $366.95
Observed on each vendor’s public listing — see how these sources are vetted. Peptide Concierge doesn’t sell peptides and isn’t affiliated with any vendor; confirm current pricing at the source.
Builds a working set shared across the stack builder, calculator, scheduler and compare.